Healthcare research is a practice that provides millions of people with hope every single year. Not only is there great humanitarian and altruistic potential in healthcare research, but the progenitors of new technologies, treatments and techniques stand to make themselves a great deal of money, too. We presently sit at the cusp of an exciting era for healthcare research and development, with many clinical trials bearing fruit while emerging digital technologies give us all reason for greater optimism. DCC are proud to provide some of the newest and most effective information processing techniques, and our goal is to enable researchers to create new clinical techniques that deliver faster, more effective and affordable treatments. These three healthcare research and development companies are in the process of conducting their own clinical trials that may lead to some incredibly important discoveries over the next few months and years, and we think they’re certainly three names worth keeping an eye on…
Proteus Digital Health
Proteus Digital Health is a California-based biotech company with grand plans. The firm has targeted a problem outlined by the World Health Organisation, who revealed that 50% of patients fail to take their medication correctly while a further 50% are prescribed the wrong drugs. As such, recovery rates are reduced, expensive treatments go to waste and antibiotic-resistant bacteria are allowed to propagate. Proteus’ solution to the problem lies in a tiny ingestible sensor, that when embedded in a tablet, will be able to digitally inform medical professionals when a treatment has been appropriately ingested. When combined with the company’s app, the sensor can communicate invaluable healthcare data that will ensure treatments are not only rigorously followed, but also correctly prescribed in the first place. Proteus’ efforts could save the healthcare industry millions, and ensure that more and more patients receive the help they need.
3D printing is one of the most exciting technological developments to have come to the fore over the last decade, with some observers claiming that it could be ‘bigger than the internet’. Texan firm TeVido Biodevices is at the forefront of the 3D printing revolution, and the company’s healthcare researchers are using the new technology to explore fascinating possibilities. The staff at TeVido are currently experimenting with ‘bioprinting’, a technique that could theoretically one day lead to 3D printed human organs and living tissue. If the company’s clinical trials are successful, then thousands of donor patients worldwide could benefit. The potential of such a medical and technological leap forwards needs no explanation!
Cancer remains one of the world’s biggest killers, with cancer researchers investing millions of pounds and countless hours of effort into combatting the disease. PARP inhibitors have provided us with a reason to be hopeful of newly effective cancer treatments to come, however, and biopharmaceutical company TESARO has had some degree of success in this highly promising area of cancer research. It is thought that PARP inhibitors could provide effective treatments for breast, ovarian and lung cancers in time, and TESARO’s phase three clinical trials are currently seeking to determine just how effective these treatments could be. Could the company’s work signal an end to destructive radio and chemotherapy treatments and even send cancers into permanent remission in time? We certainly hope so.
Healthcare research projects such as those being carried out by these three companies can give us all hope for the future. If you’re thinking of carrying out your own clinical trials and healthcare research projects this year, take a look at our accurate and reliable healthcare data capture services or contact us for more information.